← Back

SP512 Rotigotine

Transdermal Rotigotine: Double-blind, Placebo-Controlled Trial in Parkinson Disease

Year of Publication: 2007

Authors: Joseph Jankovic, Ray L. Watts, Wayne Martin, Babak Boroojerdi; SP 512 Rotigotine Transdermal System Clinical Study Group

Journal: Archives of Neurology

Citation: Arch Neurol. 2007;64:676–682

Link: https://doi.org/10.1001/archneur.64.5.676

Clinical Question

Is rotigotine delivered via a transdermal patch effective and safe for early Parkinson's disease?

Bottom Line

Transdermal rotigotine (2, 4, or 6 mg/24h) significantly improved outcomes vs placebo in early Parkinson disease: 48% vs 19% achieved ≥20% reduction in UPDRS II+III (P<0.001); LSM change in UPDRS II+III was -9.41 vs -1.57 (P<0.001) and percentage change -15.1% vs +7.3% (P<0.001). 277 patients randomized 2:1, 50 sites in the United States and Canada, 24-week treatment. Well tolerated; most common AEs were application-site reactions, nausea, and somnolence. Published Arch Neurol 2007;64:676-682.

        Major Points
        Primary endpoint: 20% responder rate in UPDRS II+III — 48% rotigotine vs 19% placebo (P<0.001).
LSM change in UPDRS II+III: -9.41 (rotigotine) vs -1.57 (placebo); P<0.001 (abstract prints these as -941 vs -157).
Percentage change in UPDRS II+III: -15.1% (rotigotine) vs +7.3% (placebo); P<0.001.
Clinical Global Impression improvement: 57% rotigotine vs 30% placebo (P<0.001); positive effect on quality of life.
277 early PD patients randomized 2:1 (181 rotigotine, 96 placebo).
Randomized, double-blind, multicenter, placebo-controlled; 50 sites in the United States and Canada; 24-week treatment.
Rotigotine transdermal system doses 2, 4, or 6 mg during 24 hours (once-daily patch, continuous delivery).
Most common adverse events: application-site reactions, nausea, and somnolence; 25/181 (14%) rotigotine patients withdrew due to adverse effects.
Sponsored by Schwarz Pharma (Neupro).
Transdermal route avoids GI absorption issues and first-pass metabolism.
Established rotigotine patch as viable monotherapy for early PD.

      

Design

Study Type: Randomized, double-blind, placebo-controlled trial

Randomization: 1

Blinding: Patients and investigators were blinded (double-blind)

Enrollment Period: Not specified

Follow-up Duration: 24 weeks

Centers: 50

Countries: USA, Canada

Sample Size: 277

Analysis: ANCOVA, last observation carried forward, exploratory analyses for secondary outcomes

Inclusion Criteria

Idiopathic PD ≤5 years
≥2 cardinal signs (bradykinesia, tremor, rigidity, postural instability)
UPDRS part III ≥10
Hoehn and Yahr stage ≤III
MMSE ≥25

Exclusion Criteria

Previous dopamine agonist or levodopa therapy (within 28 days)
Atypical parkinsonism
Major medical comorbidities
Seizures, TIA, or stroke within 1 year
Skin hypersensitivity
Pregnancy or inadequate contraception
Psychiatric disorders or cognitive impairment

Arms

Field	Rotigotine	Control
Intervention	Rotigotine transdermal patch (2, 4, or 6 mg/24h)	Placebo transdermal patch
Duration	24 weeks	24 weeks

Outcomes

Outcome	Type	Control	Intervention	HR / OR / RR	P-value
≥20% reduction in UPDRS II + III score from baseline to end of maintenance phase	Primary	19%	48%	29.00%	<0.001
LSM change in UPDRS II+III score (abstract prints as -941 vs -157; likely -9.41 vs -1.57)	Secondary	−157	−941		<0.001
Percentage change in UPDRS II+III	Secondary	+7.3%	−15.1%		<0.001
Clinical Global Impression improvement	Secondary	30%	57%		<0.001
Withdrawal due to adverse effects (rotigotine arm)	Secondary		25/181 (14%)
Application site reactions	Adverse	11%	44%
Nausea	Adverse	17%	41%
Somnolence	Adverse	20%	33%		0.005

Subgroup Analysis

Not reported

Criticisms

Study duration (24 weeks) too short to assess long-term complications like dyskinesia
QOL effects modest and largely exploratory
High rate of application site reactions may limit tolerability
No active comparator (e.g., oral dopamine agonist)

Funding

Schwarz Pharma AG

Based on: SP512 Rotigotine (Archives of Neurology, 2007)